Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey db can you add a chart since you are the mod now?
Thanks Banker for your post. We need more of those to lift our spirits. It has been a tough ride as of late, hopefully we will see better days ahead. Thanks again.
The other thing is how do we spread the word on this little gem?
Agree whole hardily! Good news.
The only thing I got as far as the Fda and China trials were we would be hearing from Watson direct regarding the US and I was given no timetable for China. I will keep digging.
Its was funny, I was digging yesterday for news, and I couldn't get a straight answer. I guess this was why. Lets see if we can get this stock moving again. Good thing I was able to pick up some more in the .80's.
News Out.
Stellar Pharmaceuticals Issued Uracyst(R) Patents in the United States and China
Email
Print
Companies:STELLAR PHAMACEUTICL
Related Quotes
Symbol Price Change
SLXCF.OB 0.93 0.00
Press Release Source: Stellar Pharmaceuticals Inc. On Wednesday July 28, 2010, 7:30 am
LONDON, ONTARIO--(Marketwire - 07/28/10) - Stellar Pharmaceuticals Inc. (OTC.BB:SLXCF - News) ("Stellar" or "the Company"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced today that it has now been issued patents ("the patents") that are central to one of its lead products, Uracyst® (a sterile sodium chondroitin sulfate solution, 2%) for the treatment of interstitial cystitis/painful bladder syndrome ("IC/PBS"), by both the Chinese Patent Office and the U.S. Patent and Trademark Office. As previously disclosed, the issuance of the patents had been subject to the Company completing final formalities, including the payment of applicable fees.
The Chinese Letters Patent No. 1758920 covers pharmaceutical compositions that comprise the greater and superior dosage size of chondroitin sulfate, and the use of those compositions for the treatment of IC/PBS. The U.S. Patent No. 7772210, entitled "Cystitis Treatment with High Dose Chondroitin Sulfate," describes the treatment of IC/PBS by instillation of an optimized dose of chondroitin sulfate.
Peter Riehl, Stellar's President and Chief Executive Officer, commented, "As awareness and acceptance of Uracyst® as the preferred treatment for IC/PBS continues to grow amongst physicians and patients in global markets, it is important this opportunity is well protected. With patents already issued in Canada, the United States (a low dose patent) and Australia, and with numerous additional international patents pending, these two additional patents expand Stellar's already formidable intellectual property estate."
About Uracyst®
It is believed that over 70% of IC/PBS patients have defects in their bladder glycosaminoglycan layers. The glycosaminoglycan ("GAG") layer is a mucosal lining of the bladder that acts as a protective barrier against irritants and toxins in the urine and defends against bacterial adherence. When the GAG layer is damaged, these irritants and toxins in the urine seep through, causing an irritation to the bladder wall. This results in increased frequency and urgency to void (up to 60 times a day). Many IC/PBS patients also experience severe pelvic pain. These symptoms can be debilitating and have a serious impact on a patient's quality of life.
Chondroitin sulfate (ChS) is believed to be the major GAG component responsible for the barrier function. Uracyst® was developed to replenish this defect in IC/PBS patients.
Uracyst® 2% (400 mg) ChS dose has been shown to be the ideal dosage to saturate the bladder, thus restoring the barrier function. Instilled fluid volume of Uracyst® 20 mL also allows patients to retain the treatment in the bladder for a longer period of time, enabling a better uptake of the delivered dosage and a faster onset of symptomatic relief. Uracyst® is also one of the most cost effective treatments for these patients. Combine treatment efficacy with the most cost effective therapy and it becomes understandable why Uracyst® is becoming the product of choice in treating IC/PBS.
About Stellar Pharmaceuticals Inc.
Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc® and NeoVisc® Single Dose, for the symptomatic treatment of osteoarthritis; and Uracyst®, its patented technology for the treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Both NeoVisc and Uracyst have their CE Mark certification for the European Community. Stellar also has an in-licensing agreement for NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. For more information, please visit the company's website at www.stellarpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
Contact:
Contacts:
Company Contact
Stellar Pharmaceuticals Inc.
Peter Riehl
President & CEO
(519) 434-1540
corpinfo@stellarpharma.com
Stellar Pharmaceuticals Inc.
Arnold Tenney
Chairman
(416) 587-3200
www.stellarpharma.com
Investor Contact
Kilmer Lucas Inc.
Stephen Kilmer
President
(905) 690-2400 ext. 21
stephen@kilmerlucas.com
Media Contact
Kilmer Lucas Inc.
Leonard Zehr
Managing Director
(905) 690-2400 ext. 41
len@kilmerlucas.com
Related Headlines
Stellar Pharmaceuticals Issued Uracyst(R) Patents in the United States and China - Marketwire
STELLAR PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits - EDGAR Online
Stellar Pharmaceuticals Allowed Uracyst(R) Patent in United States of America - Marketwire
STELLAR PHARMACEUTICALS INC Financials - EDGAR Online Financials
STELLAR PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits - EDGAR Online
Related Message Boards
STELLAR PHAMACEUTICL
There are no comments yet
Post a Comment
Sign in to post a comment, or Sign up for a free account.
Sponsored Links
Free Investment Report Stock Picks
Investment Experts FREE Email Penny Stock Alerts for Smart Investing.
www.KillerPennyStocks.com
Buy Stocks for $4
No Account or Investment Minimums. No Inactivity Fees. Start Today.
www.ShareBuilder.com
$87 Million stock market Winner
California Option Trader Makes $87 Million in stock market in 1 Year.
www.virtualinvestingclub.com
Penny Stock Portfolio up 8782% since '04
Trading low priced stocks. Up 180% in 2009. Un-biased. Free Trial.
www.pennystocksweekly.com
Top Stories
Comcast 2Q profit dips on NBC Universal deal costs - AP
Sprint Nextel posts first subscriber gain in 3 yrs - AP
Boeing 2Q profit falls; 747-8 may slip into 2011 - AP
WellPoint's 2Q profit rises 4 percent - AP
ADVERTISEMENT
Tech Ticker Recent Posts
10 Things You Need to Know: Morning Edition - Gregory White
Double-Dip? "Resilience" of Oil Prices Saying "Something Different", Chris Edmonds Says - Peter Gorenstein
Big Bucks for Big Energy CEOs: "It's Been a Tremendous Decade" - Aaron Task
View More
Subscribe to Topics
Top Stories
Add Alert
SLXCF.OB Headlines
Add Alert
See all RSS links
ADVERTISEMENT
Thats like a pimple on a bulls ass. Bfd..
Tell me about it. I wish I was in glasses boat. dreammin.
The world of the haves and have nots........... I wish Qasp would catch fire, than maybe I could have that steak. Right now its pure rice and beans for me.
You live and learn buddy.
The key word in the PR is installed. That means they got paid for the unit.
NEWS!! 3rd sim for IOT. Nice.
Its funny with this stock you either need to buy and hold, or not even look to buy at all. Nothing happens overnight with this company.
This is starting to get painful. Ferris needs to inform shareholders of current events in a hurry before he loses the faithful.
Thats what the joke was. Transparent. We were better off when Rainmaker and his crew were around. At least there were some entertaining posts.
What happened to Ferris keep this transparent?? Why would he buy stock at .055? Was it just for effect?? Not good to keep shareholders in the dark. JMO
Hey felix due we have a clue as to when earnings will be released, or when Dutchess will finally be paid off. Thanks
Didn't this come out a couple of days ago??
its in my opinion that Dean owes all of us ihubers an apology for misleading us for the last year. Jmo
Banker how do you feel now?? Is it still a good time to buy qasp??
Hey Glasses where's banker who said he was waiting for 1-2 dollars to sell some of his shares??jbo
Hey Glasses what other words of wisdom do you have for us? I know you have been digging hard for solid information. What have you unturned?
Just a question, will it ever get to the point where it will be a good selling opportunity?? This is getting real old.
LOL. :)
I'm not 100 percent convinced it is a scam. I know quite a few individuals including myself who have quite a bit invested here. We wouldn't tie our money up if we thought otherwise.
Not worth the ink it was published on....
The Swift was all Bs .JMO
Well its been a struggle but were back over a dollar. I stand corrected. Back down to .99c
Down 15 plus percent on this crazy low volume. What a crock. Has Vitra just gone to sleep??
Like your confidence there big boy. Lets hope your right. There is a lot at stake here for many of us.
Its only a matter of time till we get the China approval. Everyones very tight lipped.
Starting to get some traction again. They just had their shareholder meeting last wk. I'm trying to find out what went on.
Thought this would qualify as good news, and the stock is down 10%. Can't figure this one out anymore.
Wouldn't call this exploding... When it goes up by pennies than thats a different story.
I'll believe it when I see. The old saying zip it and put in your pocket applies to Taco. Were all just waiting to need one guy to Bs the rest of us....
Hey Taco what happened to that PR you were promised today????
From what I've been told it takes time to make these relationships. Especially when you not paying anyone to pump your own stock. This is all real, and they will catch the eye of other investment houses other than Cowen. Its all good..
Getting themselves some exposure in the investment community.
Very strange. I know this company was in New york last week work on a few items.